Neuroblastoma: Selected Readings

A selection of peer-reviewed articles and book chapters written by physicians in Memorial Sloan Kettering's Neuroblastoma Program follows. Journal articles include links to the National Library of Medicine's PubMed database, where you can read abstracts and full-text articles when available, and find “LinkOut” listings of additional credible sources of information about neuroblastoma on the Web.

Reviews

1. Principles and Practice of Immunotherapy

Cheung NK. Chapter 34. Therapeutic antibodies and immunologic conjugates. In Clinical Oncology 3rd ed. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (ed). Elsevier, Churchill, Livingstone. 2008.

Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 25(1):67-77, 2007. [PubMed]

Cheung NK. Chapter 32. Therapeutic antibodies and immunologic conjugates. In Clinical Oncology 3rd ed. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (ed). Elsevier, Churchill, Livingstone. 2004.

Cheung NK and Sondel PM. Chapter 14: Immunology and immunotherapy. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Modak S, Cheung NK. Antibody-based targeted radiation to pediatric tumors. J Nucl Med. 46(1 Suppl):157S-63S, 2005. [PubMed]

Cheung NK, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematology Oncology Clinics of North America. 15(5): 853-866, 2001. [PubMed]

Kramer K, Cheung NK. Antibody-based diagnostic and therapeutic innovations for human cancer. Comprehensive Therapy 27: 183-194, 2001. [PubMed]

Cheung NKV, Yu A: Immunotherapy of Neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (editors): Neuroblastoma. Amsterdam, Elsevier Science B.V., pp 541-546, 2000.

Larson SM, Divgi C, Sgouros G, Cheung NKV, Scheinberg DA: Monoclonal Antibodies: Basic Principles - Radioisotope Conjugates. In: DeVita VT, Hellman S, Rosenberg SA (editors.): Biologic Therapy of Cancer - Principles and Practice. Philadelphia, J.B. Lippincott Company, pp 396-412, 2000.

Biologic Therapy of Cancer -Principles and Practice. Philadelphia, J.B. Lippincott Company, 396-412, 2000.

Cheung NK. Monoclonal antibody-based therapy for neuroblastoma. Current Oncology Reports 2:547-553, 2000. [PubMed]

2. Neuroblastoma

Kushner BH, Cheung NK. Neuroblastoma: Linking a Common Allele to a Rare Disease. New England Journal of Medicine 358:2585-2593, 2008. [PubMed Abstract]

Kushner BH, Cheung NK. What factors predict a favorable outcome in young children with disseminated neuroblastoma? Nat Clin Pract Oncol. 3:242-243, 2006. [PubMed Abstract]

Kushner BH, Cheung NK. Neuroblastoma—from genetic profiles to clinical challenge. New England Journal of Medicine 353: 2215-2217, 2005. [PubMed Abstract]

Kushner BH, Cheung NK. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 47:863-864, 2006. [PubMed Abstract]

Cheung NKC, Cohn S (Editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Cheung NK and Cohn SL. Chapter 19: Perspectives and future directions. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Cheung NKC, Kushner BH: Neuroblastoma. In: Finberg L (ed). Saunders Manual of Pediatric Practice. Philadelphia, WB Saunders Co., 466-468, 1998.

Cheung NKV, Kushner BH, LaQuaglia M, Lindsley K: Treatment of Advanced Stage Neuroblastoma. In: Reghavan D, Scher HI, Leibel SA, Lange P (editors): Principles and Practice of Genitourinary Oncology. Philadelphia, J.B. Lippincott Company, 1101-1111, 1997.

Kushner BH, LaQuaglia M, Cheung NKV: Therapeutic Approach to Low-Risk and Intermediate-Risk neuroblastoma. In: Reghavan D, Scher HI, Leibel SA, Lange P (editors): Principles and Practice of Genitourinary Oncology. Philadelphia, J.B. Lippincott Company, 1085-1094, 1997.

Bonilla MA, Cheung NK. Clinical progress in neuroblastoma. Cancer Investigation 12: 644-653, 1994.[PubMed]

Kushner BH, Cheung NKV: Neuroblastoma: an overview. Hematology/Oncology Annals 1:189-201, 1993.

Kushner BH, Cheung NKV: Neuroblastoma. In: Horwich A (ed): Combined Chemotherapy and Radiotherapy in Clinical Oncology. Kent, England, Edward Arnold, pp 223-238, 1992.

Kushner BH, Cheung NK. Neuroblastoma. Pediatric Annals.17:269-76, 278-84, 1988.[PubMed]

Clinical Application of Anti-GD2 Monoclonal Antibody 3F8

1. Intravenous Injection of Naked Antibody

Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A Polymorphism Is Correlated With Clinical Outcome Following Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor. J Clinical Oncology 24:2885-2890, 2006. [PubMed Abstract]

Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatric Blood & Cancer, 48:430-434, 2007. [PubMed Abstract]

Kushner BH, Kramer K, Cheung NK. Phase II trial of 3F8 monoclonal antibody and granulocyte-macrophage colony-stimulating factor for neuroblastoma. Journal of Clinical Oncology 19: 4189-4194, 2001.[PubMed]

Cheung NK, Kushner BH, Yeh SD, Larson SM. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. International Journal of Oncology 12:1299-1306, 1998.[PubMed]

Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology 36:227-230, 2001.[PubMed]

Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM.: Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. Journal of Clinical Oncology 16:3053-60, 1998.[PubMed]

Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8 - a phase I study in patients with neuroblastoma and malignant melanoma. Journal of Clinical Oncology 5:1430-1440, 1987.[PubMed]

2. Intravenous Injection of Radiolabeled Antibody

Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. Health Physics 92:33-39, 2007. [PubMed Abstract]

Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, Macapinlac H, Finn RD, Arbit E, Cheung NK. Development of a method to measure kinetics of radiolabeled monoclonal antibody in human tumors with applications to microdosimetry: Positron emission tomography studies of iodine-124 labeled 3F8 monoclonal antibody in glioma. European Journal of Nuclear Medicine 20:402-409, 1993.[PubMed]

Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, Graham MC, Di Resta G, Bendriem B, Daghighian F, et al. PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. Journal of Nuclear Medicine 33:2020-2023, 1992.[PubMed]

Yeh SD, Larson SM, Burch L, Kushner BH, Laquaglia M, Finn R, Cheung NK. Radioimmunodetection of neuroblastoma with 131I-3F8: Correlation with biopsy, 131-I-metaiodo-benzylguanidine (MIBG) and standard diagnostic modalities. Journal of Nuclear Medicine 32:769-776, 1991.[PubMed]

Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics 18: 357-366, 1991.[PubMed]

Fletcher BD, Miraldi FD, Cheung NK. Comparison of radiolabeled monoclonal antibody and magnetic resonance imaging in the detection of metastatic neuroblastoma in bone marrow: Preliminary results. Pediatric Radiology 20:72-75, 1989.[PubMed]

Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies. Int J Rad Appl Instrum B.16:111-1120, 1989.[PubMed]

Miraldi FD, Nelson AD, Kraly C, Ellery S, Landmeier B, Coccia PF, Strandjord SE, Cheung NK. Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161:413-418, 1986.[PubMed]

3. Intrathecal Injection of Radiolabeled Antibody

Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK. Phase I study of targeted radioimmunotherapy for Leptomeningeal Cancers using Intra-Ommaya 131I-3F8. Journal of Clinical Oncology 25:5465, 2007. [PubMed Abstract]

Kramer K, Cheung NK, Humm JL, Dantis E, Finn R, Yeh SJ, Antunes NL, Dunkel IJ, Souwedaine M, Larson SM. Targeted radioimmunotherapy for leptomeningeal cancer using 131-I-3F8. Medical and Pediatric Oncology 35:716-718, 2000.[PubMed]

4. Bone Marrow Purging with 3F8

Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcription-PCR: Utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 94:3042-3048, 2002.[PubMed]

Stein J, Strandjord S, Saarinen U, Warkentin P, Gerson S, Lazarus H, Von Hoff D, Coccia P, Cheung NK. In vitro treatment of autologous bone marrow from neuroblastoma patients with anti-GD2 monoclonal antibody and human complement: a pilot study. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC (editors): Prog Clin Biol Res, Vol 271: Advances in Neuroblastoma Research. New York, Alan Liss, 1988, pp 237-24812637475[PubMed]

Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung NK. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Research 45:5969-5975, 1985.[PubMed]

Research on Anti-Neuroblastoma Monoclonal Antibodies

1. Glucan Enhancement of Antibody Activity

Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 173(2):797-806, 2004.[PubMed]

Cheung NK, Modak S. Oral (1„_3),(1„_4)-ƒÒ-D-glucan synergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clinical Cancer Research 8:1217-1223, 2002. [PubMed]

Cheung NK, Modak S, Vickers A, Knuckles B. Oral ƒÒ-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunology and Immunotherapy. 51:557-564, 2002.[PubMed]

2. Complement and Tumor Cytotoxicity

Imai M, Landen C, Ohta R, Cheung NKV and Stephen Tomlinson. Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer. Cancer Research 65: 10562-10568, 2005.[PubMed]

Chen S, Caragine T, Cheung NK, Tomlinson S. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma Cancer Research 60: 3013-3018, 2000.[PubMed]

Chen S, Caragine T, Cheung NK, Tomlinson S. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. American Journal of Pathology 156:1085-1091, 2000.[PubMed]

Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 197:444-459, 1997.[PubMed]

Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Complement killing of human neuroblastoma cells: a cytotoxic antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. Molecular Immunology 27:957-964, 1990. [PubMed]

Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. Journal of Clinical Investigation 81:1122-1128, 1988.[PubMed]

3. ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity)

Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Research, 58: 2844-2849, 1998.[PubMed]

Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol (PI)-linked FcRIII for monoclonal antibody (MoAb)-mediated neutrophil (PMN) anti-human tumor cytotoxicity. Blood 79:1484-1490, 1992.[PubMed]

Munn DH, McBride M, Cheung NK. The role of the low affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Research 51:1117-1123, 1991. [PubMed]

Kushner BH, Cheung NK. Clinically effective monoclonal antibody 3F8 mediates non-oxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Research 51:4865-4870, 1991.[PubMed]

Munn DH, Cheung NK. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. Journal of Experimental Medicine 172:231-237, 1990.[PubMed]

Munn DH, Garnick MB, Cheung NK. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and anti-tumor cytotoxicity in nonhuman primates. Blood 75:2042-2048, 1990.[PubMed]

Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. Journal of Experimental Medicine 170:511-526, 1989.[PubMed]

Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941, 1989.[PubMed]

Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Research 47:6600-6605, 1987.[PubMed]

4. Anti-Idiotypic Antibody

Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3' antibody was associated with long-term survival following anti-GD2 antibody therapy of stage 4 neuroblastoma. Clinical Cancer Research 6:2653-2660, 2000.[PubMed]

Cheung NK, Guo HF, Cheung IY. Correlation of anti-idiotype network with survival following anti-GD2 monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. Medical and Pediatric Oncology 35:635-637, 2000.[PubMed]

Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, Heller G, Larson SM. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Research. 54:2228-2233, 1994.[PubMed]

Cheung NK, Canete A, Cheung IY, Ye JN, Liu C. Disialoganglioside GD2 anti- idiotypic monoclonal antibodies. International Journal of Cancer 54:499-505, 1993.[PubMed]

5. Radiolabeled Anti-GD2 Antibody for Imaging and Therapy

Fonti R, Cheung NK, Bridger GJ, Guo HF, Abrams MJ, Larson SM. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging ganglioside GD2-positive tumors. Nuclear Medicine and Biology 26:681-686, 1999.[PubMed]

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross organ beta doses. Nuclear Medicine and Biology 23: 1-8, 1996. [PubMed]

Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, et al. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model. Nuclear Medicine and Biology 22:87-93, 1995.[PubMed]

Finn R, Cheung NK, Divgi C, St Germain J, Graham M, Pentlow K, Larson SM. Technical challenges associated with the radiolabeling of monoclonal antibodies utilizing short-lived, positron emitting radionuclides. Int J Rad Appl Instrum B. 18:9-13, 1991. [PubMed]

Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, Adams RB, Miraldi F. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. Journal of the National Cancer Institute 77:739-745, 1986.[PubMed]

Cheung NK, Neely JE, Landmeier B, Nelson D, Miraldi F. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. Journal of Nuclear Medicine 28:1577-1583, 1987.[PubMed]

6. Monoclonal Antibody 3F8 and Tumor/Normal Tissue Reactivity

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK. Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Clinical Cancer Research, 4:2135-2139, 1998.[PubMed]

Lammie GA, Cheung NKV, Gerald W, Rosenblum M, Cordon-Cardo C: Ganglioside GD2 expression in the human nervous system and in neuroblastomas - An immunohistochemical study. International Journal of Oncology 1993 3:909-915, 1993.

Ye JN, Cheung NK. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. International Journal of Cancer 50:197-201, 1992.[PubMed]

Saito M, Yu RK, Cheung NK. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochemical Biophysical Research Communications 127:1-4, 1985.[PubMed]

Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Research 45:2642-2649, 1985.[PubMed]

7. Single-chain Fv Fragment

Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM.. Single chain Fv-streptavidin substantially improved therapeutic index in multi-step targeting directed at disialoganglioside GD2. Journal of Nuclear Medicine 45: 867-877, 2004.[PubMed]

Onda M, Wang QC, Guo HF, Cheung NK, Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Research 64:1419-24, 2004.[PubMed]

Cheung NK, Guo HF, Modak S, Cheung IY. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybridoma and hybridomics 22:209-218, 2003.[PubMed]

Cheung NK, Guo HF, Modak S, Cheung IY. Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. Hybridoma and hybridomics 21:433-443, 2002.[PubMed]

Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling enhances survival and proliferation in genetically modified activated human primary T lymphocytes. Journal of Experimental Medicine 188: 619-626, 1998.[PubMed]

8. Novel Antibodies for Neuroblastoma

Luther N, Cheung NK, Dunkel IJ, Fraser JF, Edgar MA, Gutin PH, Souweidane MM. Intraparenchymal and intratumoral interstitial injection of anti-glioma antibody antibody 8H9. Neurosurgery 2008 ( in press).

Modak S, Guo HF, Humm JL, Smith-Jones PM, Larson SM, Cheung NK. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biotherapy and Radiopharmaceuticals 20:534-546,2005.[PubMed]

Modak S, Gerald W, Cheung NK. Disialoganglioside GD2 and novel tumor-restricted antigen 8H9: potential targets for antibody-based immunotherapy against desmoplastic small round cell tumor. Medical and Pediatric Oncology 39:547-551, 2002.[PubMed]

Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Research 61:4048-4054, 2001.[PubMed]

9. Cytotoxic T-lymphocytes Specific for Ganglioside GD2

Zhao XJ, Cheung NK. GD2 oligosaccharide: target for cytotoxic T lymphocytes. Journal of Experimental Medicine 182: 67-74, 1995.[PubMed]

10. Vaccines

Ragupathi G, Yeung KS, Leung PC, Lee M, Lau CB, Vickers A, Hood C, Deng G, Cheung NK, Cassileth B, Livingston P. Evaluation of Widely Consumed Botanicals as Immunological Adjuvants. Vaccines, 2008 (in press) [PubMed Abstract]

Detection of Microscopic Disease

Cheung IY, Ambros PF. Chapter 11.7. Minimal Residual Disease Measurement. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

1. Using Anti-GD2 Antibodies to Detect Microscopic Marrow Disease

Cheung NK. Detecting neuroblastoma using bone marrow aspiration and bone marrow biopsy. Journal of Pediatric Hematology Oncology. 22:86-88, 2000.[PubMed]

Cheung NK, Heller G, Kushner BH, Kramer K. Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate? Medical and Pediatric Oncology. 32:84-87, 1999.[PubMed]

Cheung NK, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? Journal of Clinical Oncology 15:2807-2817, 1997.[PubMed]

Frantz CN, Ryan DH, Cheung NV, Duerst RE, Wilbur DC. Sensitive detection of rare metastatic human neuroblastoma (NB) cells in bone marrow (BM) by two-color immunofluorescence and cell sorting. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC, (editors.): Prog Clin Biol Res, Vol 271: Advances in Neuroblastoma Research. New York, Alan Liss, 1988, pp 249-262.[PubMed]

Cheung NK, Von Hoff DD, Strandjord SE, Coccia PF. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. Journal of Clinical Oncology 4:363-369, 1986.[PubMed]

2. Using GD2-Synthase as a Disease Marker in Quantitative RT-PCR

Cheung IY, Sahota A, Cheung NK. Measuring circulating neuroblastoma cells by quantitative RT-PCR: correlation with its paired bone marrow and standard disease markers. Cancer 101:2303-2308, 2004.[PubMed]

Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NKV. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. Journal of Clinical Oncology 21(20):3853-3858, 2003.[PubMed]

Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcription-PCR: Clinical utility in evaluating adjuvant therapy in neuroblastoma. Journal of Clinical Oncology 21:1087-1093, 2003. [PubMed]

Cheung IY, Lo Piccolo MS, Collins N, Kushner BH, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcription-PCR: Utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 94:3042-3048, 2002.[PubMed]

Lo Piccolo MS, Cheung NK, Cheung IY. GD2 Synthase: a new molecular marker for detecting neuroblastoma. Cancer 92:924-931, 2001.[PubMed]

Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time RT-PCR. Clinical Cancer Research 7:1698-1705, 2001.[PubMed]

3. Other Molecular Markers of MRD

Cheung IY, Feng Y, Gerald W, Cheung NK. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clinical Cancer Research, 2008 (in press).

Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NK. Cyclin D1: A novel molecular marker of minimal residual disease in metastatic neuroblastoma. Journal of Molecular Diagnostics. 9:237-241. 2007. [PubMed Abstract]

Cheung IY, Vickers A, Cheung NK. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. International Journal of Cancer 119:152-156, 2006. [PubMed Abstract]

Chi SN, Cheung NK, Cheung IY. Expression of SSX-2 and SSX-4 in neuroblastoma. International Journal of Biological Markers, 17: 219-223, 2002.[PubMed]

Cheung NKV, Norris M: Detection of Microscopic Residual Tumors in Bone Marrow. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (editors): Neuroblastoma. Amsterdam, Elsevier Science B.V., 2000, pp 333-340.

Cheung IY, Chi SN, Cheung NK. Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Medical and Pediatric Oncology 35:632-635, 2000.[PubMed]

Cheung IY, Cheung NK. Detection of microscopic disease: comparing histology, immunocytology (IC), and RT-PCR of tyrosine hydroxylase (TH), GAGE and MAGE. Medical and Pediatric Oncology 36: 210-212, 2001.[PubMed]

Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and RT-PCR of multiple molecular markers. Clinical Cancer Research 4:2801-2805, 1998.[PubMed]

Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clinical Cancer Research 3:821-826, 1997.[PubMed]

Molecular Genetics of Neuroblastoma

Lavarino C, Garcia I, Makintosh C, Cheung NK, Domenech G, Rios J, Perez N, Rodriguez E, de Torres C, Gerald WL, Tuset E, Acosta S, Beleta H, de Alava E, Mora J. Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Medical Genomics 2008, 1:36. [PubMed Abstract]

Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and demonstrates that multiple genes are targeted by regional alterations in DNA copy number. Cancer Research 66:6050-6062, 2006. [PubMed Abstract]

Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Research 65: 2565-2571, 2005.[PubMed]

Gerald WL. Chapter 9. Molecular pathology of neuroblastic tumors based on genome-wide expression analysis. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Su WT, Alaminos M, Mora J, Cheung NK, La Quaglia MP, Gerald WL. Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genet Cytogenet. 154:131-7, 2004. [PubMed]

Mora J, Alaminos M, De Torres C, Illei P, Qin J, Cheung NK, Gerald WL. Comprehensive analysis of the 9p21-24 region in neuroblastoma suggests a role for genes mapping to 9p22-24 in the biology of favorable stage 4 tumors. Br J Cancer. 91:1112-8, 2004. [PubMed]

Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M.. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J. Natl Cancer Inst. 96(16):1208-19, 2004. [PubMed]

Alaminos M, Mora J, Cheung NK, Smith A, Qin J, Chen L, Gerald WL. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Research 63:4538-46, 2003. [PubMed]

Oppenheimer O, Alaminos M, Gerald WL. Genomic medicine and neuroblastoma. Expert Review Molecular Diagnosis 3:39-54, 2003. [PubMed]

Mora J, Cheung NK, Oplanich S, Chen L, Gerald WL. Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Research 62:1761-1767, 2002.[PubMed]

Mora J, Cheung NK, Gerald WL. Genetic heterogeneity and clonal evolution in neuroblastoma. British Journal of Cancer 85:182-9, 2001.[PubMed]

Mora J, Cheung NK, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clinical Cancer Research 7:1358-1361, 2001.[PubMed]

Mora J, Cheung NK, Juan G, Illei P, Cheung I, Akram M, Chi S, Ladanyi M, Cordon-Cardo C, Gerald WL. Neuroblastoma originates from a stem cell capable of developing along multiple lineages. Cancer Research 61:6892-6898, 2001.[PubMed]

Mora J, Cheung NK, Chen L, Qin J, Gerald W. Survival analysis of clinical, pathologic and genetic features in neuroblastoma presenting as local-regional diseases. Cancer 91:435-442, 2001.[PubMed]

Mora J, Akram M, Cheung NK, Chen L, Gerald WL. Laser-capture microdissected schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. Medical and Pediatric Oncology 35:534-537, 2000.[PubMed]

Mora J, Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Fazzari M, Heller G, Chen L, Gerald WL. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. Journal of Molecular Diagnostics 2:1-9, 2000.[PubMed]

Kushner BH, Cheung NK. Allelic loss of chromosome 1p in neuroblastoma. New England Journal of Medicine. 334:1608-1609, 1996.[PubMed]

Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer. 57:1887-1893, 1986.[PubMed]

Kushner BH, Helson L. Monozygotic siblings discordant for neuroblastoma: etiologic implications. Journal of Pediatrics. 107:405-409, 1985.[PubMed]

Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature. Journal of Clinical Oncology. 3:117-1120, 1985.[PubMed]

Prognostic Factors in Neuroblastoma

Mora J, Lavarino C, Alaminos M, Cheung NK, Rios J, Torres C, Illei P, Juan G, Gerald WL. Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. Genes Chromosomes and Cancer 46:385-396, 2007. [PubMed Abstract]

Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Research 66:2826-2833, 2006. [PubMed Abstract]

Alaminos M, Gerald WL, Cheung NK. Prognositic value of MYCN and ID2 overexpression in neuroblastoma. Pediatric Blood & Cancer 45: 909-915. [PubMed]

Mora J, Gerald WL, Qin J, Cheung NK. Evolving significance of prognostic markers associated with treatment improvement in stage 4 neuroblastoma. Cancer 94:2756-2765, 2002.[PubMed]

Mora J, Gerald WL, Qin J, Cheung NK. Molecular genetics of neuroblastoma and the implications for clinical management. A review of the MSKCC experience. Oncology 6:263-268, 2001.[PubMed]

Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N. Prognostic significance of EPHB6, EFNB2 and EFNB3 expressions in neuroblastoma. Medical and Pediatric Oncology 35:656-658, 2000.[PubMed]

Kramer K, Gerald W, LeSauteur L, Uri Saragovi H, Cheung NK. Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma. Clinical Cancer Research 2: 1361-1367, 1996.[PubMed]

Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NK. Monoclonal antibody to human TrkA: diagnostic and therapeutic potential in neuroblastoma. European Journal of Cancer 33: 2090-2091, 1997.[PubMed]

Kramer K, Cheung NK, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, LeSauter L, Saragovi HU. Correlation of MYCN amplification, TrkA and CD44 expression with clinical stage in 250 patients with neuroblastoma. European Journal of Cancer 33:2098-2100, 1997.[PubMed]

LeSauteur L, Cheung NK, Lisbona R, Saragovi HU. In vivo imaging of nerve growth factor receptors with small molecule analogs of nerve growth factor. Nature Biotechnology 14:1120-1122, 1996.[PubMed]

Neuroblastoma Stem Cells

Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, Cheung NK, Ross RA. Characteristics of Stem Cells from Human Neuroblastoma Cell Lines and in Tumors. Neoplasia.6 :838-845, 2004.[PubMed]

Clinical Management of Neuroblastoma

1. Clinical Spectrum

Kushner BH, Kramer K, Laquaglia MP, Modak S, Cheung NK. Liver involvement in neuroblastoma: The Memorial Sloan Kettering Experience supports treatment reduction in young patients. Pediatric Blood & Cancer, 2005. [PubMed]

Kushner BH, LaQuaglia MP, Modak S, Cheung NK. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. Medical and Pediatric Oncology, 41: 80-82, 2003.[PubMed]

Kushner BH, Kramer K, LaQuaglia MP, Modak S and Cheung NKV. Neuroblastoma in adolescents and adults: the Memorial Sloan Kettering experience. Medical and Pediatric Oncology, 2003. [PubMed]

Kushner BH, Kramer K, Cheung NK. Chronic neuroblastoma. Cancer 95:1366-1375, 2002.[PubMed]

Kushner BH, Helson L, Lane JM, Hajdu SI. Metastatic neuroblastoma after 52 years of apparent dormancy. New England Journal of Medicine 315:196-197, 1986.[PubMed]

Kushner BH, Vogel R, Hajdu SI, Helson L. Metastatic neuroblastoma and testicular involvement. Cancer. 56:1730-1732, 1985.[PubMed]

2. Nuclear Imaging

Kushner BH.. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 45:1172-1188, 2004. [PubMed]

Abramson SJ, Shulkin BL. Chapter 10. Anatomic and Funtional Imaging. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.<

Cheung NK, Kushner BH. Should we replace bone scintigraphy plus CT with MR imaging for staging of neuroblastoma? Radiology. 226:286-287, 2003.[PubMed]

Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. Journal of Clinical Oncology 21:1082-1086, 2003.[PubMed]

Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. Journal of Clinical Oncology 19: 3397-3405, 2001.[PubMed]

3. Treatment of Local-Regional/4s Neuroblastoma

Kushner BH, Cohn SL. Chapter 11.1. Treatment of low-risk neuroblastoma. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Kushner BH, Cohn SL. Chapter 11.2. Treatment of high-risk neuroblastoma. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Kushner BH, LaQuaglia MP, Kramer K, Cheung NK.. Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol. 26:35-9, 2004.[PubMed]

Kushner BH, Kramer K, LaQuaglia MP, Cheung NK.. Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-GD2 immunotherapy. Journal of Pediatric Hematology/Oncology 25:515-519, 2003.[PubMed]

Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Ambros P, Ambros I, Ladanyi M, Eddy J, Bonilla MA, Gerald W. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. European Journal of Cancer 33:2117-2121, 1997.[PubMed]

Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Ladanyi M, Gerald WL. INSS stage 1 neuroblastoma: a prospective study and literature review. Journal of Clinical Oncology 14: 2174-2180, 1996.[PubMed]

Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Gerald WL, Ladanyi M, Gilbert F, Rosenfield NS, Yeh SD. Survival from locally invasive or metastatic neuroblastoma without cytotoxic therapy. Journal of Clinical Oncology 14:373-381, 1996.[PubMed]

Kushner BH, Cheung NK. Neonatal screening and management of biologically low-risk localized neuroblastoma. Journal of Pediatric Hematology Oncology.17:180-181, 1995.[PubMed]

Kushner BH, LaQuaglia MP, Cheung NK. Rethinking management of localized neuroblastoma. Journal of Clinical Oncology. 11:1832-1834, 1993.[PubMed]

4. Chemotherapy

Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan-temozolomide for relapsed or refractory neuroblastoma. Journal of Clinical Oncology 24:5271-5276. [PubMed Abstract]

Kushner BH, Kramer K, Laquaglia MP, Modak S, Yataghene K, Cheung NK. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. Journal of Clinical Oncology, 22:4888-92, 2004. [PubMed]

Kushner BH, Kramer K, Modak S, Cheung NK. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer 103: 858-862, 2005. [PubMed]

Matthay KK,Cheung NKV. Chapter 11.3. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005. [PubMed]

Kramer K, Kushner BH, Cheung NK. Oral Topotecan for Refractory and Relapsed Neuroblastoma: A Retrospective Analysis. Journal of Pediatric Hematology/Oncology 25:601-605, 2003. [PubMed]

Kushner BH, Heller G, Kramer K, Cheung NK. Granulocyte colony-stimulating factor (G-CSF) and multiple cycles of alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 89:2122-2130, 2000.[PubMed]

Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Medical and Pediatric Oncology 35:468-474, 2000.[PubMed]

Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. Journal of Clinical Oncology 17:3221-3225, 1999.[PubMed]

Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD. In vitro anti-tumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. Journal of Pediatric Hematology/Oncology. 20:136-139, 1998.[PubMed]

Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, Eddy J, Gerald WL, Heller G, Cheung NK. Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. Journal of Clinical Oncology 12:2607-2613, 1994.[PubMed]

Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. Journal of Clinical Oncology 9:1050-1058, 1991.[PubMed]

Kushner BH, O'Reilly RJ, LaQuaglia M, Cheung NK. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 66:1095-1100, 1990.[PubMed]

Kushner BH, Cheung NK. Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet. 336:253-254. 1990.[PubMed]

Kushner BH, Helson L. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients. Journal of Clinical Oncology, 5:1746-1751, 1987.[PubMed]

5. Surgical Resection

LaQuaglia MP. Chapter 11.4. The role of surgery in the treatment of neuroblastoma. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Sandberg DI, Bilsky MH, Kushner BH, Souweidane MM, Kramer K, Laquaglia MP, Panageas KS, Cheung NK.. Treatment of spinal involvement in neuroblastoma patients. Pediatr Neurosurg. 39: 291-8, 2003.[PubMed]

La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK. The impact of gross total resection on local control and survival in high-risk neuroblastoma. Journal of Pediatric Surgery 39:412-417, 2004. [PubMed]

Medary I, Aronson D, Cheung NK, Ghavimi F, Gerald W, La Quaglia MP. Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. Annals of Surgical Oncology 3:521-525, 1996.[PubMed]

La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK. Stage 4 neuroblastoma diagnosed at more than one year of age: gross total resection and clinical outcome. Journal of Pediatric Surgery 29:1162-1164, 1994.[PubMed]

6. Radiation Therapy for Neuroblastoma

Wolden SL, Barker CA, Kushner BH, Bodduluri H, Della-Biancia C, Kramer K, Modak S, Cheung NK. Brain-sparing radiotherapy for neuroblastoma skull metastases. Pediatr Blood Cancer 50:1163-1168, 2008. [PubMed Abstract]

Modak S, Pandit-Taskar N, Kushner BH, Kramer K, Smith-Jones P, Larson S, Cheung NK Transient sialoadenitis: A complication of (131)I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer 50:1271-1273, 2008. [PubMed Abstract]

Wolden SL, Haas-Kogan D. Chapter 11.5. Radiation therapy. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Cheung NK, Kushner BH. Risks outweighed benefits from local radiation for non-stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys.54:1575, 2001.[PubMed]

Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NK. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. Journal of Clinical Oncology. 19:2821-2828, 2001.[PubMed]

Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosen N, Abramson S, Cheung NV. Local control with multimodality therapy for stage 4 neuroblastoma. International Journal of Radiation Oncology Biology Physics 46:969-974, 2000.[PubMed]

7. Bone Marrow Transplantation

Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined, with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplantation 28:551-556, 2001.[PubMed]

Kushner BH, O'Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M, Cheung NK. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. Journal of Clinical Oncology 9:274-279, 1991. [PubMed]

Kushner BH, Gulati SC, Kwon JH, O'Reilly RJ, Exelby PR, Cheung NK.High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer. 68:242-7, 1991.[PubMed]

Kushner BH, Gulati SC, O'Reilly RJ, Heller G, Cheung NK. Autografting with bone marrow exposed to repeated courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophoshamide in vitro. Medical and Pediatric Oncology 18:454-458, 1990.[PubMed]

Gulati SC, Kwon JH, Kushner B, Cheung NK, Atzpodien J, Shum K, Clarkson BD. In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide. Cancer Investigation 7:417-422, 1989.[PubMed]

8. CNS and Leptomeningeal Metastasis

Kramer K, Pranzatelli MR. Chapter 13. Management of neurologic complcations. Cheung NK and Cohn S (editors). Neuroblastoma. Springer. ISBN: 3-540-40841-x. 2005.

Kramer K, Kushner BH, Allen JC, Krol G, Cheung NK. Favorable biology neuroblastoma presenting with leptomeningeal metastases? A case presentation. Journal of Pediatric Hematology/Oncology 26:703-705, 2004. [PubMed]

Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system: the Memorial Sloan Kettering Cancer Center experience and a literature review. Cancer 91:1510-1519, 2001.[PubMed]

9. Opsoclonus-Myocolonus

Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Annals of Neurology 53:347-353, 2003.[PubMed]

Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Canete A, Delattre JY, Thompson SJ, Posner JB. Major histocompatibility (MHC) proteins, anti-Hu antibodies and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 75:99-109, 1994. [PubMed]

Experimental Therapeutics

1. Antibody Therapy of Leptomeningeal Disease

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clinical Cancer Research. 10:6985-92, 2004. [PubMed]

Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, (225)Ac-HuM195, in Nonhuman Primates. Journal of Nuclear Medicine. 45: 129-137, 2004. [PubMed]

Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunology Immunotherapy 49:259-266, 2000.[PubMed]

Bergman I, Barmada MA, Heller G, Griffin JA, Cheung NK. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody 3F8. International Journal of Cancer. 82:538-548, 1999.[PubMed]

Bergman I, Pohl CR, Venkataramanan R, Burckart GJ, Stabin M, Barmada MA, Griffin JA, Cheung NK. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. Journal of Immunotherapy. 22:114-123, 1999. [PubMed]

Bergman I, Burckart GJ, Pohl CR, Venkataramanan R, Barmada MA, Griffin JA, Cheung NK. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. Journal of Pharmacology and Experimental Therapeutics 284: 111-115, 1998.[PubMed]

Bergman I, Ahdab-Barmada M, Kemp SS, Griffin JA, Cheung NK. A rat model of leptomeningeal human neoplastic xenografts. Journal of Neuro-Oncology 34:221-231, 1997.[PubMed]

Kramer K, Cheung NK, Humm J, DiResta G, Arbit E, Larson S, Finn R, Rosenblum M, Nguyen H, Gonzalez G, Liu C, Yang YF, Mendelsohn ME, Gillio AP. Pharmacokinetics and acute toxicology of intraventricular 131I-monoclonal antibody targeting disialoganglioside in non-human primates. Journal of Neurooncology 35:101-111, 1997.[PubMed]

Bergman I, Arbit E, Rosenblum M, Larson SM, Heller G, Cheung NK. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. Journal of Neuro-Oncology 15:235-242, 1993.[PubMed]

2. Differentiation Therapy

Wu L, Bernard-Trifilo JA, Lim Y, Lim ST, Mitra SK, Uryu S, Chen M, Pallen CJ, Cheung NK, Mikolon D, Mielgo A, Stupack DG, Schlaepfer DD. Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 27:1439-1448, 2008. [PubMed Abstract]

Oppenheimer O, Cheung NK, Gerald WL. Transcriptional programs associated with retinoic acid induced differentiation in neuroblastoma. Mol Cancer Ther 6(4):1300-1309, 2007. [PubMed Abstract]

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clinical Cancer Research.7:962-970, 2001.[PubMed]

Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Research. 61:3591-3594. 2001.[PubMed]

Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind R, Marks PA, Richon VM, LaQuaglia MP. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Medical and Pediatric Oncology 35:577-581, 2000.[PubMed]

Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Research 59:4392-4399, 1999.[PubMed]

3. Chemotherapy

Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. Journal of Pediatric Hematology Oncology. 20:136-139, 1998.[PubMed]

4. Arsenic Trioxide

Soignet S, Bienvenu B, Cheung N, Vongphrachanh P, Calleja E, Pezzulli S, Ellison R, Spriggs D, Warrell RP. Clinical and pharmacologic study of arsenic trioxide (As2O3) in patients with solid tumors. 36th Annual Meeting of American Society of Clinical Oncology. 19:201a, 2000.

Late Effects of Treatment

Laverdiere C, Cheung NK, Kushner BH, Kramer K, Modak S, Laquaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA. Long-term complications in survivors of advanced stage neuroblastoma. Pediatric Blood & Cancer. 45:324-332, 2005. [PubMed]

Laverdiere C, Gurney J, Sklar CA. Chapter 18. Late effects of treatment. Cheung NK and Cohn S (editors). Neuroblastoma. Springer.ISBN: 3-540-40841-x. 2005. [PubMed]

1. Leukemia

Kushner BH, Laquaglia MP, Kramer K, Modak S, Cheung NK. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomide. Pediatr Blood Cancer. 2008 (in press). [PubMed Abstract]

Robinson BW, Cheung NK, Kolaris CP, Jhanwar SC, Choi JK, Osheroff N, Felix CA. Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood 111:3802-3812, 2008. [PubMed Abstract]

Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD, Carroll M, Liu M, Osheroff N, Cheung NK, Slater DJ, Ried T, Knutsen T, Blair IA, Felix CA.. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 22(52):8448-59, 2003.[PubMed]

Raffini LJ, Slater DJ, Rappaport EF, Lo Nigro L, Cheung NK, Biegel JA, Nowell PC, Lange BJ, Felix CA. Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4 and CDK6. Proceedings of the National Academy of Science (USA) 99: 4568-4573, 2002.[PubMed]

Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ, Felix CA. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors Proceedings of the National Academy of Sciences (USA) 97:2814-2819, 2000.[PubMed]

Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan Kettering experience and a literature review. Journal of Clinical Oncology 16:3880-3889, 1998.[PubMed]

Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. Association of CYP3A4 with treatment-related leukemia. Proceedings of the National Academy of Sciences (USA) 95:13176-13181, 1998.[PubMed]

Felix CA, Hosler MR, Provisor D, Salhany K, Sexsmith EA, Slater DJ, Cheung NK, Winick NJ, Strauss EA, Heyn R, Lange BJ, Malkin D. The p53 Gene in pediatric therapy-related leukemia and myelodysplasia. Blood 87:4376-4381, 1996. [PubMed]

2. Cardiac Toxicity

Gupta M, Steinherz PG, Cheung NK, Steinherz L. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Medical and Pediatric Oncology. 40:343-347, 2003.[PubMed]

Kushner BH, Cheung NK. Cyclophosphamide and the heart. Journal of Clinical Oncology 9:529-530, 1991.[PubMed]

3. Neuropsychological Followup

Butler RW, Cheung NKV, Eddy J. Increased intellectual functioning in children with neuroblastoma. Child Neuropsychology 2: 77-82, 1996.

4. Ototoxicity

Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxocity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417-422, 2006. [PubMed Abstract]